Navigation Links
Shire plc: Excellent Performance Across All Areas of the Business and Accelerating New Product Sales Drive Revenue Growth of 36%
Date:2/21/2008

BASINGSTOKE, England and PHILADELPHIA, February 21 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, NASDAQ: SHPGY) the global specialty biopharmaceutical company announces results for the twelve months to December 31, 2007 - a year which has seen significant growth in launched products.
- All $ values are US$

Financial Highlights

2007 Full Year Q4 2007

- Product sales up 41% to $2,170m - Product sales up 55% to $661m

- New product sales $489m, 23% of product - New product sales $210m, 32%

sales(1) of product sales (1)

- Total revenues up 36% to $2,436m - Total revenues up 46% to

$725m

- Non GAAP Earnings per ADS up 38% to - Non GAAP Earnings per ADS up

$2.95 67% to $0.94

- US GAAP Earnings per ADS down 592% to - US GAAP Earnings per ADS up

-$8.06 175% to $1.11

- Dividend up 20% (in US$ terms)

(1) New product sales include VYVANSE, LIALDA/MEZAVANT, DYNEPO, ELAPRASE, FOSRENOL and DAYTRANA

Matthew Emmens, Chief Executive Officer, commented:

"Shire had an excellent 2007, growing sales from our portfolio of both new and established products by a total of 41% and raising revenue guidance throughout the course of the year. We generated substantial cash inflows from operations of $475 million, after expending $156 million on the acquisition of new product candidates in both our Human Genetic Therapies and Specialty Pharmaceutical businesses. Based on these strong results we were able to bring forward several new R&D programs.

During the year, we undertook three major new product launches - VYVANSE, LIALDA / MEZAVANT and DYNEPO - which have gone well and also continued the roll-out of ELAPRASE and FOSRENOL into new geographies. These products, together with
'/>"/>

SOURCE Shire plc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Shire plc: Correction Re Website
2. Shires ELAPRASE(R) (idursulfase) Approved in Mexico for Treatment of Hunter Syndrome
3. Shire Engages Palio
4. Texas Boy Receives Wheelchair From New Hampshire Couples Recently Deceased Granddaughter
5. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
6. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
7. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
8. Shire plc: Board Changes
9. David Mott Appointed Non Executive Director at Shire
10. Correction: Shire plc: Third Quarter 2007 results date notification November 1, 2007
11. Shire Divests Non-Core Product Portfolio to Almirall
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014 According to ... (Consumables, Instruments, Services), Methods (Phenotypic, Genotypic), Applications (Pharmaceutical, Diagnostic, ... Characterization) - Global Forecasts to 2019" published ... estimated at $896.5 Million in 2014 and ... 2019, growing at a CAGR of 5.9% ...
(Date:7/28/2014)... 28, 2014   Propeller Health , the FDA-cleared ... hire of Brad Towle as Senior Vice ... for driving the company,s sales growth, customer acquisition and ... and specifically his past role in the development of ... at this pivotal time in the industry," said ...
(Date:7/28/2014)... Francisco, California (PRWEB) July 28, 2014 ... USD 604.40 billion by 2020, according to a new ... coupled with the rising demand for effective vaccines and ... patients with unmet medical needs is expected to drive ... the need to enhance agricultural productivity via the use ...
(Date:7/28/2014)... Research and Markets has announced the ... report to their offering. ... technique used to determine the size of a particle in ... to analyze the size of particles as it can affect ... performed to determine the behavior and nature of a material, ...
Breaking Biology Technology:Microbial Identification Market worth $1,194.1 Million by 2019 2Microbial Identification Market worth $1,194.1 Million by 2019 3Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 2Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 3Global Biotechnology Market Worth $604.40 Billion by 2020: Grand View Research, Inc 4Global Particle Size Analysis Market 2014-2018 2
... (Nasdaq: SIAL ) is pleased to announce ... Chief Information Officer, effective August 16, 2010. In his ... systems function and will report to Rakesh Sachdev, Sr. ... Borg (age 50) brings over two decades ...
... Unaudited Second Quarter Results -- re> SHENYANG, China, Aug. 17 /PRNewswire-Asia-FirstCall/ -- ... ... ... var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... Statement re ProAmatine -- PHILADELPHIA, Pennsylvania, August 17, 2010 ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
Cached Biology Technology:Sigma-Aldrich Announces Appointment of Magnus Borg as Vice President and Chief Information Officer (CIO) 23SBio Inc. Announces Unaudited Second Quarter Results 23SBio Inc. Announces Unaudited Second Quarter Results 33SBio Inc. Announces Unaudited Second Quarter Results 43SBio Inc. Announces Unaudited Second Quarter Results 53SBio Inc. Announces Unaudited Second Quarter Results 63SBio Inc. Announces Unaudited Second Quarter Results 73SBio Inc. Announces Unaudited Second Quarter Results 83SBio Inc. Announces Unaudited Second Quarter Results 93SBio Inc. Announces Unaudited Second Quarter Results 103SBio Inc. Announces Unaudited Second Quarter Results 113SBio Inc. Announces Unaudited Second Quarter Results 123SBio Inc. Announces Unaudited Second Quarter Results 133SBio Inc. Announces Unaudited Second Quarter Results 143SBio Inc. Announces Unaudited Second Quarter Results 153SBio Inc. Announces Unaudited Second Quarter Results 163SBio Inc. Announces Unaudited Second Quarter Results 173SBio Inc. Announces Unaudited Second Quarter Results 183SBio Inc. Announces Unaudited Second Quarter Results 19Shire plc - Statement re ProAmatine 2Shire plc - Statement re ProAmatine 3Shire plc - Statement re ProAmatine 4Shire plc - Statement re ProAmatine 5Shire plc - Statement re ProAmatine 6
(Date:7/29/2014)... PARIS, 29 JULY 2014 With thirty days to ... for the FEBS-EMBO 2014 Conference are well underway. The ... Biochemical Societies (FEBS), EMBO, and the French Society for ... Saturday, 30 August to Thursday, 4 September at the ... 2014 Conference is the largest meeting for the life ...
(Date:7/29/2014)... it affects 1 in 100,000 people characterized by a ... cause remains unknown, a new study by a team of ... in Germany and other European institutions confirms for the first ... on 6 July in Nature Genetics , is an ... swallow, a sphincter in the lower esophagus opens, allowing food ...
(Date:7/28/2014)... drugs already approved by the U.S. Food and Drug ... growth of certain bacterial pathogens inside human cells, including ... fever. The findings, published in mBio , the ... demonstrate a new way of identifying non-antibiotic drugs that ... A handful of drugs on the list inhibit the ...
Breaking Biology News(10 mins):Counting down to FEBS-EMBO 2014 in Paris, France 2Mysterious esophagus disease is autoimmune after all 2New route to identify drugs that can fight bacterial infections 2
... was launched today by the Chinese National Space Administration ... Centre, Sichuan, atop a Long March 3A rocket. ... to land robotic explorers on the Moon before 2020. ... first is to make three-dimensional images of many lunar ...
... and Ludwigshafen, Germany-October 24, 2007-Harvard University,s Office of ... agreement to jointly establish the BASF Advanced Research ... of Engineering and Applied Sciences (SEAS) the initiative ... and schools throughout the University. Set up ...
... Researchers at the University of Minnesotas Stem Cell Institute ... used to study how human embryonic stem cells differentiate. ... Experimental Biology and Medicine. Researchers know very little ... fully understand these cells self renewal capacity and pluripotency, ...
Cached Biology News:Chang'e-1 -- new mission to Moon lifts off 2BASF and Harvard University announce extensive research collaboration 2
karyopherin alpha2 (2G7)...
... The PowerEase 500 Power Supply ... electrophoresis. It offers extensive programming ... four custom methods for you ... preferences. The simple intuitive PowerEase ...
... real-time or pre-programmed liquid switching ... or general liquid-handling research applications. ... accuracy. Run experiments ... Microprocessor-based for accuracy and flexibility ...
... entry-level automated perfusion system. For real-time ... physiology, biophysics, electrochemistry, or general liquid-handling ... 10 millisecond accuracy Run experiments ... for accuracy and flexibility Turnkey ...
Biology Products: